Masatsugu Hamaji

Dr. Masatsugu Hamaji


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Masatsugu HamajiMasatsugu Hamaji
Masatsugu Hamaji
SASyed Osman Ali
Syed Osman Ali
BBBryan M. Burt
Bryan M. Burt

1 April 2015 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Masatsugu HamajiMasatsugu Hamaji
Masatsugu Hamaji
SASyed Osman Ali
Syed Osman Ali
BBBryan M. Burt
Bryan M. Burt

1 May 2015 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Masatsugu HamajiMasatsugu Hamaji
Masatsugu Hamaji
SASyed Osman Ali
Syed Osman Ali
BBBryan M. Burt
Bryan M. Burt

29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MCMarco Chiappetta
Marco Chiappetta
Ugo GrossiUgo Grossi
Ugo Grossi
ISIsabella Sperduti
Isabella Sperduti
SMStefano Margaritora
Stefano Margaritora
Giuseppe MarulliGiuseppe Marulli
Giuseppe Marulli
Filippo LococoFilippo Lococo
Filippo Lococo
Background: Optimal recurrent thymoma management remains arguable because of limited patient numbers, and relatively late and variable recurrence patterns. Given the absence of high-quality evidence and relatively small study cohorts, we performed a quantitative meta-analysis to determine the outcome of surgical and non-surgical approaches assessing the five-year overall survival (5y overall survival (OS)) in patients with recurrent thymoma. Methods: We performed a comprehensive literature search and analysis according to PRISMA guidelines of studies published from 1 January 1980 until 18 June 2020 from PubMed/MEDLINE, EMBASE, and Scopus. We included studies with the cohorts’ superior to 30 patients describing recurrent thymoma treatment, comparing surgical and non-surgical approaches reporting survival data. Results: Literature search revealed 3017 articles. Nine studies met all inclusion criteria and were selected for the meta-analysis. The recurrences were local/regional in 73–98% of cases and multiple in 49–72%. After treatment, 5y OS ranged from 48–77% and 10y OS from 37–51%. The quantitative meta-analysis showed a better outcome comparing surgical vs other treatments. Two studies showed statistically significant risk differences in the 5y OS favoring complete resection. After pooling results of seven studies using the random model, the combined 5y OS risk difference was 0.39, with lower and upper limits of 0.16 and 0.62, respectively (p = 0.001), and a moderate heterogeneity among studies (p = 0.098, I2 = 43.9%). Definitive conclusions could not be drawn regarding the prognostic impact of myasthenia gravis, histology, and patterns of relapse reported in literature. Conclusions: Surgical treatment after thymoma recurrence is associated with a significant better 5y OS; therefore, surgical resection should be preferred in all technically feasible cases.

22 December 2020 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
HKHidenao Kayawake
Hidenao Kayawake
TCToyofumi F Chen-Yoshikawa
Toyofumi F Chen-Yoshikawa
FGFumiaki Gochi
Fumiaki Gochi
STSatona Tanaka
Satona Tanaka
KYKimiko Yurugi
Kimiko Yurugi
HDHiroshi Date
Hiroshi Date
OBJECTIVES: Few studies have evaluated the outcomes of lung transplantation (LTx) in recipients with preformed donor-specific antibodies (DSAs). This study investigated the postoperative changes in preformed DSAs based on prospectively collected data of DSAs, and the influences of preformed DSAs on postoperative outcomes among LTx recipients. METHODS: Between July 2010 and December 2019, 216 recipients underwent LTx (81 living-donor lobar lung transplants and 135 deceased-donor lung transplants). We reviewed 8 cases with preformed DSAs to determine postoperative changes in DSAs and compared postoperative outcomes between recipients with and without DSAs. RESULTS: The preoperative mean fluorescence intensity of preformed DSAs ranged from 1141 to 14 695. Two recipients experienced antibody-mediated rejection within 2 weeks after LTx. DSAs disappeared in 7 recipients; however, 1 recipient experienced the relapse of DSAs and died from chronic lung allograft syndrome (CLAD), whereas 1 recipient had persisting DSAs within the study period and died from CLAD. Neither overall survival (OS) nor CLAD-free survival was significantly different between recipients with and without DSAs (P = 0.26 and P = 0.17, respectively). However, both OS and CLAD-free survival were significantly lower in recipients with DSAs against HLA class II than in those without these antibodies {5-year OS: 25.0% [95% confidence interval (CI): 0.9–66.5%] vs 72.1% (95% CI: 63.8–78.9%), P = 0.030 and 5-year CLAD-free survival: 26.7% (95% CI: 1.0–68.6%) vs 73.7% (95% CI: 66.5–79.5%), P = 0.002}. CONCLUSIONS: Prognosis in recipients experiencing the relapse of preformed DSAs and those with persisting DSAs may be poor. The recipients with anti-HLA class II preformed DSAs had a significantly worse prognosis.

15 October 2021 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
TMTetsuji Moriya
Tetsuji Moriya
Masatsugu HamajiMasatsugu Hamaji
Masatsugu Hamaji
AYAkihiko Yoshizawa
Akihiko Yoshizawa
RMRyo Miyata
Ryo Miyata
MNMisa Noguchi
Misa Noguchi
HDHiroshi Date
Hiroshi Date
To clarify survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) as first-line treatment for postoperative recurrence. A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of non-small-cell lung cancer (NSCLC) harbouring EGFR gene mutations at our institution between August 2002 and October 2020. Therapeutic response, adverse events, progression-free survival (PFS) and overall survival (OS) were investigated. Survival outcomes were assessed using the Kaplan–Meier analysis. The Cox proportional hazards model was used for univariable and multivariable analyses. Sixty-four patients were included in the study. The objective response and disease control rates were 53% and 92%, respectively. Grade 3 or greater adverse events were noted in 4 (6.3%) patients, including 1 patient (1.6%) of interstitial pneumonia. The median follow-up period was 28.5 months (range 3–202 months). The total number of events was 43 for PFS and 23 for OS, respectively. The median PFS was 18 months, and the median OS was 61 months after EGFR-TKI treatment. In multivariable analysis, osimertinib showed a tendency to prolong PFS [hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.12–1.1; P = 0.071], whereas the micropapillary component was significantly associated with shorter OS (HR 2.1, 95% CI 1.02–6.9; P = 0.045). EGFR-TKIs as first-line treatment appeared to be a reasonable treatment option in selected patients with postoperative recurrent EGFR-mutated NSCLC. Osimertinib and the micropapillary component may be prognostic factors.